Jiuzi Holdings, Inc. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, dated October 23, 2023, reports on a private placement transaction and an upcoming shareholder meeting for Jiuzi Holdings, Inc., a foreign private issuer. The filing details a securities purchase agreement entered into on October 20, 2023, with non-U.S. persons under Regulation S.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or existing debt levels. The primary financial data relates to the proposed capital raise:
- Aggregate Purchase Price: Approximately $50 million.
- Units Sold: 113,636,360 units.
- Price Per Unit: $0.44.
- Unit Composition: One ordinary share (par value $0.018) and one warrant to purchase three shares.
- Warrant Exercise Price: $1.10 per share.
- Warrant Expiration: Five years from issuance.
Material Changes
The material change reported is the execution of the Securities Purchase Agreement (SPA) for the private offering. This transaction is subject to conditions, including shareholder approval and the accuracy of representations and warranties. No comparative financial data or changes in operating metrics versus prior periods are provided in this filing.
Guidance, Outlook, and Risks
Shareholder Meeting: The Company plans to hold an Extraordinary General Meeting on November 30, 2023, at 10:00 AM EST in a hybrid format to seek approval for the SPA and the Offering.
Conditions and Risks: The transaction is contingent upon shareholder approval. The SPA includes customary representations regarding the absence of undisclosed material adverse effects and legal proceedings affecting the transaction. The warrants are subject to anti-dilution provisions and may be exercised cashlessly after six months if no effective registration statement is available.
Investor Verification Checklist
- Verify the outcome of the Extraordinary General Meeting scheduled for November 30, 2023, to confirm if the $50 million offering was approved.
- Review the full text of the Securities Purchase Agreement (Exhibit 99.1) and Warrant (Exhibit 99.2) for specific covenants and redemption rights.
- Confirm the final closing date and actual proceeds received, as the filing only reports the agreement to sell.
- Assess the dilution impact of 113,636,360 new shares plus the potential issuance of warrant shares (up to 340,909,080 shares).